Novo Nordisk’s SWOT analysis: diabetes giant faces fierce competition in GLP-1 stock battle

Novo Nordisk reported robust Q4 2024 financial results, driven by its GLP-1 portfolio with 20.9% revenue growth and an 84.26% gross profit margin, and projects 19-27% top-line growth for 2025, exceeding consensus expectations while its stock appears undervalued. Despite intensifying competition from Eli Lilly, the company is strategically expanding product indications, notably Wegovy for MASH, and advancing a strong pipeline, including Alzheimer's and next-generation assets, to sustain its market leadership and address past supply challenges.

Analysis

Novo Nordisk (NVO) presents a compelling but complex investment case, characterized by strong current fundamentals set against intensifying competition. The company's Q4 2024 performance was robust, with 20.9% revenue growth and an industry-leading 84.26% gross profit margin, driven by outperformance in its core GLP-1 franchise. Forward guidance for 2025 reinforces this strength, with projected top-line growth of 19-27% surpassing consensus expectations. Valuation appears attractive, as the stock trades at a P/E ratio of 14.66 relative to its growth outlook and is considered undervalued by InvestingPro's fair value model. However, this positive picture is challenged by the significant competitive threat from Eli Lilly (LLY), whose products are expected to continue capturing U.S. market share. NVO is proactively responding through strategic DTC partnerships and a new NovoCare platform offering Wegovy at a discounted cash price of $499 per month to defend its position. Future growth prospects are heavily tied to pipeline execution, with the recent Wegovy label expansion for MASH poised to add an estimated $1.9 billion in peak revenue, and key data readouts in 2H 2025 for Alzheimer's (EVOKE) and next-generation assets serving as major potential catalysts.

Key Decisions for Investors

• Investors should consider the attractive valuation, highlighted by a 14.66 P/E ratio against 19-27% projected growth, while weighing this against the escalating competitive pressure from Eli Lilly.
• Closely monitor the market share dynamics between NVO's Wegovy/Ozempic and LLY's Zepbound/Mounjaro, as this is the primary determinant of future revenue performance and pricing power.
• The effectiveness of new direct-to-consumer strategies, particularly the NovoCare platform, should be evaluated as a key indicator of the company's ability to defend its franchise against both branded and compounded competition.
• Upcoming pipeline catalysts in 2H 2025, especially the Phase 3 EVOKE data in Alzheimer's, represent a significant binary event that could materially re-rate the stock and should be a primary focus for long-term thesis validation.